Randomized Comparison of Interferon-a, Hydroxyurea, and Busulfan in Chronic Myeloid Leukemia: Response to Kantarjian and Talpaz and to Tura and Baccarani
We appreciate the letters by Kantarjian and Talpaz and by Tura and Baccarani regarding our report. ' Kantarjian and Talpaz compare their retrospective study on 274 interferon-a (R%)-treated chronic myeloid leukemia (CML) patients' with the IFN arm of our randomized prospective study that compares I F N with hydroxyurea and busulfan. Although the quality of the group's studies is acknowledged, it cannot be expected that a randomized study with defined inclusion criteria that follows the intention-to-treat principle will yield identical results. The goal of our study was to analyze the impact of IFN on the duration of the chronic phase and on survival in newly diagnosed chronic-phase CML requiring treatment as compared with standard busulfan or hydroxyurea. There were almost no entry restrictions, particularly no age limits (our oldest patient was 85 years at diagnosis), to obtain information on the true benefit of the respective therapies in a nonpreselected patient population representative of general hematologic practice. In addition, it should be noted that our protocol required monotherapies. In consideration of these differences it is not surprising that Kantarjian and Talpaz' patient population contains almost twice as many low-risk patients as our patient population and much fewer intermediate-and high-risk patients (Table 1) . This difference correlates with a median age of 41 years in the Houston patients as compared with 47.4 years in our patients.
Kantarjian and Talpaz note that only 3 1 % of our patients attained complete hematologic responses as compared with 80% in their group. However, the rates of complete and partial hematologic responses together are similar in both studies (83% in our patients and 87% in the Houston patients) despite the differences in patient group For personal use only. on August 30, 2017. by guest www.bloodjournal.org From composition. This good response rate was achieved although the noresponse group, because of the intention-to-treat principle in randomized studies, comprised 6 patients who never received IFN. However, minor differences in definition and procedures may cause major differences in response rates. Looking at the definitions of complete hematologic response, we noted that the Houston group required a normal differential with no blasts, promyelocytes, or myelocytes.' Our definition also requires the absence of metamyelocytes, unless bands and metamyelocytes together are 5% or less.
Furthermore, because almost one half of the Houston patients received IFN in combination with other drugs such as hydroxyurea or IFN y , which are known to influence the degree of hematologic response, a higher complete hematologic remission rate had to be expected. The combination of I F N with hydroxyurea or similar drugs would have been a protocol violation in our study. Preliminary data of an ongoing study of our group that analyzes the combination of IFN and hydroxyurea show that the rate of complete hematologic remissions is indeed much higher (58% by now).
We agree with the concept that achieving minimal tumor burden in CML prolongs survival as discussed by us previously in the context of lower white blood cell (WBC) counts obtained with hydroxy~rea.~ However, the observation of more cytogenetic responses in the Houston patients is in line with the considerations that goodrisk patients are more likely to obtain cytogenetic responses than intermediate-and high-risk ones and that the likelihood of detecting transient responses increases with the frequency of analyses.
The second question of Kantarjian and Talpaz applies only in part, because we consider the overall hematologic response rates to be similar in the two studies. Although there was a learning period for participating physicians in the initial phase of the study, this period should not be overestimated, because the German study group has more than 20 years of expertise in performing cooperative studies (overall protocol violation rate only 10.5%). In the remaining 90% of patients the dosage of IFN depended on hematologic response (goal: WBC counts of 2 to 4 X 109L) and tolerability. The mean daily IFN dosage in our study was close to 5 X lo6 IU/m' during the first 3 months, declined to about 3.5 X lo6 IU/m2 by 12 months, and was 3 X lo6 IU/m2 at 30 months. This is not much less than in the Italian study (as opposed to what Kantarjian and Talpaz state in their letter), which reports 4.28 X IO6 IU/m2 during the first 14 months and, at least in cytogenetic nonresponders, considerably lower dosages thereafte~~ The majority of our patients reached and maintained low WBC counts under increasingly lower IFN doses. These data are compatible with the possibility that the tolerability of high doses of IFN is less in intermediate-and high-risk patients.
We therefore would agree with Kantarjian and Talpaz' assumption that different patient characteristics are an important reason for differences in results.
Concerning questions 3, 4, and 5, we agree that the frequency of cytogenetic analyses is of relevance for the recognition of cytogenetic responses. It therefore had to be expected that our lower frequency of cytogenetic analyses (half the frequency requested by our protocol) would recognize fewer cytogenetic responses. It has to be critically asked how useful a method really is that requires considerable effort and has to rely on single responses, as transient as they may be. Hematologic response probably is the better marker, as we and others have
We would expect that a truly relevant response is longer lasting and detectable by less frequent analyses than requested by Kantarjian and Talpaz. However, we do agree, and stated so in our report, that, due to the low frequency of our cytogenetic follow-up analyses, we might have missed transient cytogenetic responses and that this may be a major reason for our lower cytogenetic response rate. We also agree that the inclusion of unrecognized transient cytogenetic responders in the no-response category might falsely improve the survival outcome of nonresponders as compared with responders. It might indeed be that after prolonged observation of our patient group those with major or complete cytogenetic responses may have a relevant survival advantage, as stated in our report.
However, we would not agree that the nonrecognition of cytogenetic responders as a consequence of fewer cytogenetic analyses has any impact on survival, because the median survival of our IFNtreated patients compares favorably with that of other published series ( Table 2) . As of January 20, 1995, the median survival had not been reached at 94 months in our low-risk IFN-treated patients (n = 30) and is 47 months in our high-risk patients (n = 50), similar to the data shown by Kantarjian and Talpaz in their Table 2 . We therefore conclude that the differences in overall survival are primarily caused by the patient group composition (ratio of low-to highrisk patients, Table 1 ).
We agree with Tura and Baccarani that there are several important differences between the German' and Italian4 studies. We would first like to comment on the inclusion criteria.
Although our inclusion criteria are different from the Italian ones (no age limit and only patients requiring treatment were randomized), chronic phase was a requirement. Five (of 513) randomized patients (2 in the IFN arm) were found to have accelerated or blast phase after randomization (as mentioned in our report) and were included in the intention-to-treat evaluation.
We believe that three further objective differences between the Italian and German studies contributed to the different outcome and should be mentioned. First, our study protocol prohibited the combination of IFN with hydroxyurea as practiced in the Italian study, because strictly monotherapies were compared. The inclusion of hydroxyurea in the treatment schedule of our study might have allowed the continuation of IFN in a higher percentage of our patients. Preliminary results of our study on the Combination of IFN and hydroxyurea confirm this assumption. The second difference that possibly, at least in part, results from the different inclusion criteria is the patient group composition. The proportion of low-risk patients of the Italian study is (similar to the Houston study) much higher than that of the German study ( Table 1 ). The third difference is the treatment schedule in the hydroxyurea control arm. In our study, hydroxyurea was administered in a dosage sufficient to reach normal WBC counts, resulting in a lower tumor burden. As a consequence, our hydroxyurea-treated patients have a longer median survival (56 v 52 months) despite their much less favorable risk profile. In addition to the difference in patient group composition, we consider the good median survival time of our hydroxyurea-treated patients essential for not obtaining a significant survival difference between IFN and hydroxyurea, also because the median survival of our IFN-treated patients is not significantly different from that of other series ( Table 2) , including the Italian patients (the Italian survival curve is within the 95% confidence intervals of our survival curve).
Finally, in looking at all three studies and the impact of IFN dosage on cytogenetic response and long-time CML-free survival it 
